by Mohamed Fathima S on  April 3, 2019 at 1:05 PM Drug News
Gout-Treating drug could prevent Obesity-related Type 2 Diabetes
The arthritic condition gout-treating drug colchicine could potentially reduce complications accompanying metabolic syndrome. According to the research published in Diabetes, Endocrinology, and Metabolism, a combination of high blood pressure, high blood sugar and other conditions that elevate the risk of heart disease and type 2 diabetes could significantly reduce by the action of the drug.

Previous studies have indicated that the system-wide inflammation that occurs in obesity plays a role in the development of type 2 diabetes. In the current study, researchers led by Jack A. Yanovski, M.D., Ph.D., of NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) randomly assigned 21 study participants to received colchicine twice a day for 3 months, while 19 participants received a placebo. Colchicine suppresses a multi-protein complex called NLRP3, which triggers the inflammation seen in obesity.

Empowering Better Health

Researchers looked at several measures that reflect how well insulin works in the body to clear sugar from the blood (insulin resistance). There was no difference between the two groups in insulin resistance determined by one measure of insulin use (the frequently sampled, insulin-modified intravenous glucose tolerance test). However, the colchicine group showed improvement on the Homeostatic Model Assessment of Insulin Resistance test, which also estimates how much insulin is needed to keep blood sugar at a normal level while fasting. Those in the colchicine group also scored lower on a blood test of C-reactive protein and other tests that indicate inflammation. The authors concluded that larger studies are needed to determine if colchicine could prevent the development of type 2 diabetes in people with metabolic syndrome.

Source: Eurekalert

Most Popular on Medindia